Viewing Study NCT03609593


Ignite Creation Date: 2025-12-25 @ 1:17 AM
Ignite Modification Date: 2026-02-06 @ 11:13 AM
Study NCT ID: NCT03609593
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-02-07
First Post: 2018-07-25
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Bendamustine/rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Sponsor: Nicole Lamanna
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Lymphocytic Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Chronic Lymphocytic Leukemia (CLL) View
None Leukemia View
None Bendamustine View
None Rituximab View
None Venetoclax View